Clinical Trial Update: CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cytoreductive surgery with HIPEC using mitomycin C for platinum-resistant recurrent epithelial ovarian cancer is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Epithelial Ovarian Cancer, Platinum Resistant | Phase 3 | Status: ACTIVE_NOT_RECRUITING